We have discovered that CD8+cells actively display quiescent status in tumor environment with several pathways. Moreover, heterogeneous immune responses from different patients’ CD8+ cells have been confirmed by genomewide association study (GWAS). Therefore, heterogeneous immune responses of CD8+ cells from quiescent status to active status should be addressed by system biology for personalized immunotherapy.
Methods and Findings
After we measured mRNA expression level obtained from quiescent CD8+ cells of two liver cancer specimens, significant network with a discovery of their targeting compounds was uncovered in some subtle differences of mRNA gene expression detected in the heterogeneous responses of quiescent CD8 cells. Etoposide and taurine could inhibit REST (65%) and ERF (87%) in specimen-1; taurine inhibited both ERF and SKI and loratadine supressed SKI in specimen-2. Cytotoxic T lymphocyte (CTL) showed 61+5.6% by etoposide and 45+9% by taurine in specimen-1 and demonstrated 48+6% by taurine and 45+4% by loratadine in specimen-2.
Our results demonstrate that heterogeneous immune responses of CD8+ cells can be analysed by system biology for further personalized immunotherapy.